340B drug discounts are drifting from patients to profit, and reform is now on the table

The 340B Drug Pricing Program must be reformed to better patient health and disincentivize institutional profit-seeking behaviors, says the American College of Physicians (ACP). In a new policy, "Reforming 340B to Promote Program Integrity and Better Serve Vulnerable Populations: An American College of Physicians Policy Brief," published today in Annals of Internal Medicine, ACP issues recommendations to preserve the health and longevity of the program and its patients through policy changes.